ISSN 1662-4009 (online)

ey0020.5-14 | Basic Research | ESPEYB20

5.14. New horizons: Gonadotropin-releasing hormone and cognition

V Prevot , M Tena-Sempere , N Pitteloud

Brief summary: This literature review summarized the recent advances in our understanding of the GnRH system throughout life and its implication in the brain development beyond its conventional role in reproductive control.During embryonic development GnRH neurons migrate from the olfactory placode to the hypothalamus, where they control the hypothalamus–pituitary–gonadal axis (1,2). But many GnRH neurons migrate to other brain regions, such as...

ey0020.5-8 | Clinical Guidance and Studies | ESPEYB20

5.8. GnRH replacement rescues cognition in Down syndrome

M Manfredi-Lozano , V Leysen , M Adamo , I Paiva , R Rovera , JM Pignat , FE Timzoura , M Candlish , S Eddarkaoui , SA Malone , MSB Silva , S Trova , M Imbernon , L Decoster , L Cotellessa , M Tena-Sempere , M Claret , A Paoloni-Giacobino , D Plassard , E Paccou , N Vionnet , J Acierno , AM Maceski , A Lutti , F Pfrieger , S Rasika , F Santoni , U Boehm , P Ciofi , L Buee , N Haddjeri , AL Boutillier , J Kuhle , A Messina , B Draganski , P Giacobini , N Pitteloud , V Prevot

Brief summary: This study identified a new role for GnRH in higher brain function using a rodent model of Down Syndrome. It reports for the first time an improvement of cognitive functions in patients with Down Syndrome treated with pulsatile GnRH.GnRH neurons are classically described as a population of neurons located in the hypothalamus and responsible for the activation and regulation of the hypothalamic-pituitary-gonadal axis. However, the recent de...

ey0015.6-10 | Food for thought | ESPEYB15

6.10 I am your trans patient

EB Lewis , B Vincent , A Brett , S Gibson , RJ Walsh

To read the full abstract: BMJ. 2017 Jun 30;357:j2963This group of 5 transgender and non-medical professional authors has written a unique “What Your Patient is Thinking” article published in the BMJ. Their aim was to tell health care providers, and others who manage transgender people, how they want to be received and treated and what went wrong in many previous meetings with the healt...

ey0020.4-9 | Inequities and Inadequacies in DSD Diagnosis and Care | ESPEYB20

4.9. Disorders of sex development: Challenges in a low-resource country

AM Ehua , MO Moulot , KS Agbara , T Enache , SR Bankole

Brief summary: In this retrospective clinical study Ehua AM et al., reports the diagnostic and management characteristics of 13 individuals whose karyotype could be studied out of 33 DSD patients, followed over 17 years by 2 pediatric surgery departments in Abidjan.Serum testosterone could be measured only in 9 of 13 patients. Four patients were treated medically with topical androgen only. One patient had feminizing genitoplasty, and 2 had masc...

ey0016.4-13 | New Paradigms | ESPEYB16

4.13. Growth hormone-Insulin-like growth factor 1 axis hyperactivity on bone fibrous dysplasia in McCune-Albright Syndrome

D Tessaris , AM Boyce , M Zacharin , P Matarazzo , R Lala , L De Sanctis , MT Collins

To read the full abstract: Clin Endocrinol. 2018;89:56–64.McCune Albright syndrome (MAS) is a rare disorder caused by somatic gain-of-function mutations of the GNAS gene [1]. This gene encodes the α-subunit of the Gs protein and its mutations are responsible for persistent stimulation of adenylyl cyclase and dysregulated production of cyclic AMP leading to persistent o...

ey0018.3-11 | New Genes | ESPEYB18

3.11. Human type 1 Iodothyronine deiodinase (DIO1) mutations cause abnormal thyroid hormone metabolism

MM Franca , A German , GW Fernandes , XH Liao , AC Bianco , S Refetoff , AM Dumitrescu

Thyroid. 2021;31:202–207. doi: 10.1089/thy.2020.0253.This study describes a new genetic thyroid disease that might be unnoticeable in individuals with normal thyroid synthetic capacity, but may cause harm in all patients who are dependent on levothyroxine substitution such as congenital hypothyroidism, acquired hypothyroidism, or post-thyroidectomy.Three iodothyro...

ey0019.3-3 | Thyroid hormone action | ESPEYB19

3.3. Extended absorption of liothyronine from poly-zinc-liothyronine: results from a phase 1, double-blind, randomized, and controlled study in humans

AM Dumitrescu , EC Hanlon , M Arosemena , O Duchon , M Ettleson , M Giurcanu , AC Bianco

Thyroid. 2022 Feb;32(2):196-205. doi: 10.1089/thy.2021.0304. Epub 2021 Dec 31. PMID: 34641706Brief Summary: This phase 1, double-blind, randomized, single-dose, placebo-controlled, crossover study compared pharmacokinetics, pharmacodynamics, incidence of adverse events, and sleep pattern between the routinely used L-triiodothyronine (LT3) and a newly developed metal-coordinated form of LT3 (pol...

ey0017.7-2 | Clinical Guidance | ESPEYB17

7.2. Sex-specific estrogen levels and reference intervals from infancy to late adulthood determined by LC-MS/MS

H Frederiksen , TH Johannsen , SE Andersen , J Albrethsen , SK Landersoe , JH Petersen , AN Andersen , ET Vestergaard , ME Schorring , A Linneberg , KM Main , AM Andersson , A Juul

To read the full abstract: Journal of clinical endocrinology and metabolism vol. 105,3 (2020):754–768. doi: https://academic.oup.com/jcem/article/105/3/754/5624050The authors used state-of-the-art liquid chromatography tandem mass spectrometry to establish sex-specific reference ranges for estrone (E1) and estradiol (E2) throughout life and evaluate sex-differences.</...

ey0015.5-4 | New genes and gene mutations | ESPEYB15

5.4 Mutations That Alter the Carboxy-Terminal-Propeptide Cleavage Site of the Chains of Type I Procollagen Are Associated With a Unique Osteogenesis Imperfecta Phenotype

T Cundy , M Dray , J Delahunt , JD Hald , B Langdahl , C Li , M Szybowska , S Mohammed , EL Duncan , AM McInerney-Leo , PG Wheeler , P Roschger , K Klaushofer , J Rai , M Weis , D Eyre , U Schwarze , PH Byers

To read the full abstract: J Bone Miner Res 2018;33(7):1260-1271Osteogenesis imperfecta (OI) is characterized by early-onset skeletal fragility, often short stature, blue sclerae and some other features. OI is caused by mutations in the two genes encoding type I collagen, namely COL1A1 and COL1A2. Some previous reports have indicated that when the mutation involves the C-propeptide cleavage site in e...

ey0017.4-2 | Important for clinical practice | ESPEYB17

4.2. Genetic disorders in prenatal onset syndromic short stature identified by exome sequencing

TK Homma , BL Freire , RS Honjo Kawahira , A Dauber , MFA Funari , AM Lerario , MY Nishi , EV Albuquerque , GA Vasques , PF Collett-Solberg , SM Miura Sugayama , DR Bertola , CA Kim , IJP Arnhold , AC Malaquias , AAL Jorge

To read the full abstract: J Pediatr. 2019 Dec;215:192–198.Identifying the diagnosis in children with syndromic short stature and those with recognized genetic growth disorders is often challenging, as they may share many clinical features (1)(2). The candidate gene approach has many limitations in unveiling the genetic cause. Therefore, whole exome sequencing (WES) has been proposed to improve the diagnostic rate in children with short sta...